Editorially Independent content supported with advertising by Genentech
Ash Abbey, MD
Show Description +
Many patients try a series of anti-VEGF agents before they finally find a treatment that allows extended duration that meaningful affects the burden of care. Join Ash Abbey, MD, as he shares the case of a wet AMD patient who, after 3 years of treatment on various therapies, finally found an option that allowed the patient to extend to a 12-week interval.
Posted: 8/30/2024
Ash Abbey, MD
Many patients try a series of anti-VEGF agents before they finally find a treatment that allows extended duration that meaningful affects the burden of care. Join Ash Abbey, MD, as he shares the case of a wet AMD patient who, after 3 years of treatment on various therapies, finally found an option that allowed the patient to extend to a 12-week interval.
Posted: 8/30/2024
Please log in to leave a comment.